GSK announces positive headline results from Salford Lung study
UK pharma major GlaxoSmithKline (LSE: GSK) has announced positive headline results in the innovative Salford Lung Study in chronic obstructive pulmonary disease (COPD).
The pioneering study is a Phase IIIb multi-center, open label randomized controlled trial (RCT) comparing the effectiveness and safety profile of Relvar Ellipta (Breo Ellipta in the US) (FF/VI) 100/25mcg with existing COPD usual care.
Initial results show that FF/VI achieved a superior reduction in exacerbations versus usual care, which included long-acting muscarinic antagonists (LAMA). Long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS), administered as a monotherapy, dual or triple combinations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze